Key terms
About IMUX
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856. The company is headquartered in New York, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest IMUX news
Apr 05
9:38am ET
Krispy Kreme upgraded, Altice USA downgraded: Wall Street’s top analyst calls
Apr 05
4:50am ET
Analysts Offer Insights on Healthcare Companies: Immunic (IMUX) and Shockwave Medical (SWAV)
Apr 05
4:35am ET
Immunic initiated with Buy into MS readouts at Brookline
Apr 04
5:20pm ET
Immunic initiated with a Buy at Brookline
Apr 04
11:37am ET
Immunic management to meet with B. Riley
Mar 20
6:33am ET
Immunic receives notice of allowance from USPTO
Feb 25
11:29pm ET
Hold Rating on Immunic: Balancing Long-Term Potential Against Short-Term Uncertainties
Feb 23
1:01am ET
Immunic, Inc. Is Worried About This – Should You Be Worried Too?
Feb 22
1:36pm ET
Buy Rating Affirmed for Immunic Amid Progress in IMU-838 Trials and Extended Financial Runway
Feb 22
6:52am ET
Immunic Releases Insightful Investor Presentation Online
Feb 13
4:40pm ET
Immunic files to sell 55.94M shares of common stock for holders
Jan 08
11:05am ET
Biotech Alert: Searches spiking for these stocks today
No recent news articles are available for IMUX
No recent press releases are available for IMUX
IMUX Financials
Key terms
Ad Feedback
IMUX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
IMUX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
